News Focus
News Focus
Replies to #85546 on Biotech Values
icon url

Biowatch

10/29/09 12:55 PM

#85547 RE: iwfal #85546

Genta Safe Harbor statements seem beyond the norm.
The phrase "This press release may contain forward-looking statements" is usually adequate.

>>Factors that could affect actual results include, without limitation, risks associated with:
the Company's ability to obtain necessary regulatory approval for Genasense® from the U.S. Food and Drug Administration ("FDA");
the safety and efficacy of the Company's products or product candidates;
the commencement and completion of clinical trials;
the Company's assessment of its clinical trials;
the Company's ability to develop, manufacture, license and sell its products or product candidates;
the Company's ability to enter into and successfully execute license and collaborative agreements, if any;
the adequacy of the Company's capital resources and cash flow projections, the Company's ability to obtain sufficient financing to maintain the Company's planned operations, or the Company's risk of bankruptcy;
the adequacy of the Company's patents and proprietary rights;
the impact of litigation that has been brought against the Company; and
the other risks described under Certain Risks and Uncertainties Related to the Company's Business, as contained in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2008 and its most recent quarterly report on Form 10-Q. <<
icon url

exwannabe

10/29/09 9:47 PM

#85568 RE: iwfal #85546

Re: Genta

Good technical point about the assumed HR on the futility analysis. But really, why?

The only good side is that they will now have to do another R/S which means they can stop using scientific notation on the number of shares outstanding.

This company is a CTIC wannabe. How bad is that?